Imetelstat May Benefit Patients With Lower Risk MDS
Researchers sought to determine whether imetelstat would have efficacy in patients with lower risk MDS that is relapsed/refractory to erythropoiesis stimulating agents.
Diagnosis & Disease Information
Ruxolitinib Shows Promise in Treatment-Resistant PV
Researchers sought to determine whether ruxolitinib would improve clinical outcomes in patients with treatment-resistant PV.
Substantial Proportion of Patients With MDS or AML Not Considered for HCT
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS
The FDA has assigned a Prescription Drug User Fee Act goal date of August 28, 2023.
Nutrition-Related Challenges Common for Older Adults with AML, MDS
A literature review sought to identify nutritional challenges patients with acute myeloid leukemia and myelodysplastic syndrome experience.
IPSS-M Shows Strong Predictive Power in Myelodysplastic Syndrome
Researchers sought to determine whether the Molecular IPSS system would improve prognostic classification for patients with MDS.
Increased Infection, Reduced Hematopoietic Stem Cell Transplantation Rates Seen in TP53-Mutated MDS/AML
Researchers sought to determine the impact of TP53 mutations on infection and HCT rates in patients with MDS/AML.
Magrolimab Plus Azacitidine Well Tolerated With Promising Efficacy in Higher-Risk Myelodysplastic Syndrome
Researchers sought to determine whether magrolimab combined with azacitidine would be an effective treatment for patients with high-risk MDS.
Treatment Selection and Symptom Management After MDS/MDN Diagnosis
A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.
Frailty Predicts Increased Cost of Care in Myelodysplastic Syndromes
Researchers sought to determine whether a higher frailty score would be linked with cost of care in patients with MDS.
- Loading...
Loading...
Next post in Myelodysplastic Syndromes
Loading... 
Loading...